Table 3.

Clinical characteristics of BP cases treated by biologics.

Ref.	Age/sex	PASI	Medication history	Biologics treatment	Dose	Course of treatment	Anti-BP180/BP230	EOS	Outcome of BP
(24)	57/M	ND	Cyclosporin, topical corticosteroids and calcipotriol	Etanercept	50 mg qw	6 months	Anti-BP180: 175 U/ml	ND	CR
(25)	49/F	17.2	Cyclosporine, methotrexate and NB/UVB phototherapy	Etanercept	100 mg qw	12 weeks	ND	ND	CR
(26)	64/M	12	Psoralen, ultraviolet A light therapy and topical corticosteroids	Etanercept	50 mg qw then 50 mg biw	ND	ND	ND	CR
(27)	88/F	6.4	Acitretin	Ustekinumab	45 mg at week 0 and week 4, then every 12 weeks	48 months	Anti-BP180: 17 U/ml and anti-BP230: 103 U/ml	700/µl	CR
(28)	37/F	11.6	Topical corticosteroids	Ixekizumab	160 mg at week 0, then 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks	1 year	Anti-BP180: 21 U/ml and anti-BP230: 52 U/ml	ND	CR
(29)	68/M	48.5	Intermittent courses of methotrexate, acitretin, cyclosporin, phototherapy and topical therapies	Secukinumab	300 mg at weeks 1, 2, 3, and 4 and then 300 mg every 4 weeks	7 months	ND	400/µl	CR
(30)	85/F	No history of psoriasis	ND	Secukinumab	300 mg at days 1, 8, 15, 22, 50, and 83	12 weeks	Anti-BP180: 689 U/ml	ND	CR

BP, bullous pemphigoid; Ref, reference; PASI, Psoriasis area and severity index; EOS, eosinophil; qw, once a week; biw, twice a week; CR, complete remission; ND, not described; F, female; M, male.